Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.33 |
| ▸ | ADK | P55263 | 3/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24407351 | 1.00 | FGFR1 (0.33) | FGFR1POLRMTCYP3A4CYP2D6ADK | |
| SCHEMBL24407381 | 1.00 | FGFR1 (0.33) | FGFR1POLRMTCYP3A4CYP2D6ADK | |
| SCHEMBL24304934 | 0.98 | FGFR1 (0.35) | FGFR1POLRMTCYP3A4CYP2D6ADK | |
| SCHEMBL25977030 | 0.98 | FGFR1 (0.35) | FGFR1POLRMTCYP3A4CYP2D6ADK | |
| SCHEMBL25977055 | 0.98 | FGFR1 (0.35) | FGFR1POLRMTCYP3A4CYP2D6ADK | |
| SCHEMBL24305055 | 0.91 | AKT1 (0.36) | FGFR1 | |
| SCHEMBL24407356 | 0.91 | CYP3A4 (0.37) | POLRMTCYP3A4ADK | |
| SCHEMBL24407343 | 0.91 | CYP3A4 (0.37) | POLRMTCYP3A4ADK | |
| SCHEMBL24407405 | 0.91 | CYP3A4 (0.37) | POLRMTCYP3A4ADK | |
| SCHEMBL24407404 | 0.91 | CYP3A4 (0.37) | POLRMTCYP3A4ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | FGFR1 4832/4885POLRMT 361/4885CYP3A4 2205/4885 |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | FGFR1 4832/4885POLRMT 361/4885CYP3A4 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.